CytoMed Therapeutics Limited GDTC
0.89 USD -0.02 (-2.31%)
At closeNov 4, 2026, 4:00 PM EST
0.90 +0.01 +1.30%
After hours · Nov 4, 4:00 PM ET
0.8309 Day range 0.8918
0.68 52-week range 3.10
- YTD
- -33.66%
- 1 year
- -55.33%
Financial health
Altman Z-Score
-1.48 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 2
Valuation
P/E -5.1×
FY 2019 5y median -16.6× FY 2025
P/S 61.9×
FY 2019 5y median 0.0× FY 2025
P/B 3.1×
FY 2019 5y median 6.1× FY 2025
P/FCF -4.6×
FY 2019 5y median -16.3× FY 2025
EV/EBITDA -5.2×
FY 2019 5y median -17.3× FY 2025
EV/Sales 56.9×
FY 2019 5y median 0.0× FY 2025
FCF Yield -21.9%
FY 2019 5y median -6.2% FY 2025
Profitability
Gross Margin 79.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin -1476.3%
FY 2019 5y median 0.0% FY 2025
Net Margin -1227.1%
FY 2019 5y median 0.0% FY 2025
ROE -60.8%
FY 2019 5y median -60.8% FY 2025
ROIC -65.3%
FY 2019 5y median -37.8% FY 2025
ROA -49.8%
FY 2019 5y median -34.0% FY 2025
Growth (YoY)
Revenue 366.7%
FY 2019 FY 2025
Operating Income -33.1%
FY 2019 FY 2025
EPS (diluted) -54.5%
FY 2019 FY 2025
Free Cash Flow -7.1%
FY 2019 FY 2025
Financial Health
Current Ratio 5.2×
FY 2019 5y median 5.2× FY 2025
Quick Ratio 3.7×
FY 2019 5y median 3.7× FY 2025
Debt / Equity 0.1×
FY 2019 5y median 0.1× FY 2025
Net Debt / EBITDA 0.5×
FY 2019 5y median 0.5× FY 2025
Interest Coverage -229×
FY 2019 5y median -85.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31